TopoTarget A/S
Symbion
Fruebjergvej 3
DK 2100 Copenhagen
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771
www.topotarget.com
Investor News No. 02-09
Copenhagen, Denmark -13 May 2009 - TopoTarget A/S (OMX: TOPO) has announced
that data from three trials from the belinostat program will be presented at
the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, which
will be held May 29 - 2 June in Orlando, Florida.
Friday May 29 2:00 PM - 6:00 PM
Board 15 Final results of a phase I study of oral belinostat (PXD101) in
patients with solid tumors. Abstract #3531
W. K. Kelly, J. deBono, G. Blumenschein, U. Lassen, J. Zain, O. O'Connor, F.
Foss, J. Tjornelund, J. Fagerberg, D. Petrylak
Poster Display/Discussion Session
Developmental Therapeutics: Molecular Therapeutics
Display Location: Level 3, W315A
Discussion Time: 5:00 PM - 6:00 PM
Discussion Location: Level 4, Valencia Room, W415D
CME, Nursing, and Pharmacy contact hours: 1
Track(s): Developmental Therapeutics
Saturday May 30 8:00 AM - 12:00 PM
Board S7 Final results of a phase I study of oral belinostat (PXD101) in
patients with lymphoma.
Abstract #8580
J. M. Zain, F. Foss, W. K. Kelly , J. DeBono, D. Petrylak, A. Narwal, E.
Neylon, G. Blumenschein, U. Lassen, O. A. O'Connor
Generl Poster Session
Lymphoma and Plasma Cell Disorders
Location: Level 2, West Hall C
Track(s): Lymphoma and Plasma Cell Disorders
Saturday May 30 2:00 PM - 6:00 PM
Board M3 Phase II study of the histone deacetylase inhibitor belinostat in
thymic malignancies.
Abstract #7589
G. Giaccone, A. Rajan, C. Carter, R. Kelly,
A. Berman, J. Spittler, I. Espinoza-
Delgado, M. Lee, J. Trepel, P. Loehrer
General Poster Session
Lung Cancer—Local-Regional and Adjuvant Therapy
Location: Level 2, West Hall C
Track(s): Lung Cancer—Local-Regional and Adjuvant Therapy
The full abstracts will be available at www.asco.org on May 14, 2009.
TopoTarget A/S
For further information, please contact:
Peter Buhl Jensen Telephone +45 39 17 94 99
CEO Mobile +45 21 60 89 22
